Close Menu

Silence

Silence Therapeutics has named Georg Buchner as vice president of business development.
In this role, he will work with the company's chief business officer to broaden its collaborations with pharmaceutical and biotech firms.

By Doug Macron
Silence Therapeutics this week announced that it has signed a deal under which Mirna Therapeutics will evaluate two of its proprietary delivery technologies for use with Mirna's therapeutic microRNA mimics.

Silence Therapeutics this week announced that it has signed a deal under which one of its proprietary siRNA delivery technologies will be evaluated by an undisclosed “global pharmaceutical” company.

Silence Therapeutics said last week that it has received a Japanese patent covering methods for screening a therapeutic agent to treat diseases, such as cancer, related to increased Pl3-kinase pathway activity.

Silence Therapeutics has named COO Thomas Christely as its new CEO.

As part of the restructuring, Silence has lowered the headcount at its Berlin research facility to 27 from 32.

The application claims the lipid used in its Silence's AtuPlex delivery technology.

Pages

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.